Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors

Journal of Bone and Mineral Research

Volumn 19, Issue 10, 2004, Pages 1651-1660

  Van't Hof, Rob J ^a   Idris, Aymen I ^a   Ridge, Susan A ^a   Dunford, James ^a   Greig, Iain R ^a   Ralston, Stuart H ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Inhibitor; Mouse; Osteoblast; Osteoclast; Resorption

Indexed keywords

ABD 056; BIPHENYL DERIVATIVE; BUTANEDIOL; CARBOXYLIC ACID DERIVATIVE; COLONY STIMULATING FACTOR 1; ESTER DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; ALKALINE PHOSPHATASE; CARBOXYLIC ACID; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; CASPASE 3; I KAPPA B; PROSTAGLANDIN SYNTHASE; RAP1 PROTEIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW CULTURE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; COCULTURE; CONCENTRATION (PARAMETERS); HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PERIPHERAL BLOOD MONONUCLEAR CELL; RABBIT; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; DRUG EFFECT; IN VITRO STUDY; MACROPHAGE; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

ALKALINE PHOSPHATASE; ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; BONE MARROW CELLS; BONE RESORPTION; CARBOXYLIC ACIDS; CASPASE 3; CASPASES; CELLS, CULTURED; I-KAPPA B PROTEINS; MACROPHAGES; MICE; OSTEOCLASTS; OVARIECTOMY; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RAP1 GTP-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21644466561     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2004.19.10.1651     Document Type: Article

References (23)

1. Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:1504-1508.
2. Rodan GA, Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289:1508-1514.
3. Fleish A 1997 Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29:55-62.
4. Cummings SR, Chapurlat RD 2000 What proof proves about calcitonin and clinical trials. Am J Med 109:330-331.
5. Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskey E, Sampson D 2003 Medical management of hypercalcemia. Calcif Tissue Int 74:1-11.
6. Selby PL, Davie MW, Ralston SH, Stone MD 2002 Guidelines on the management of Paget's disease of bone. Bone 31:366-373.
7. Torgerson DJ, Bell-Syer SE 2001 Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 285:2891-2897.
8. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer C, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637-645.
9. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG 1995 The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 313:36-46.
10. Armour KJ, van't Hof RJ, Armour KE, Torbergsen AC, del Soldato P, Ralston SH 2001 Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). Arthritis Rheum 44:2185-2192.
11. Ralston SH 1997 Nitric oxide and bone: What a gas! Br J Rheumatol 36:831-838.
12. Armour KJ, Greig IR, Ralston SH, van't Hof RJ 2003 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions. United Kingdom W003/03721.2003. Date filed: October 31, 2003.
13. Frith JC, Rogers MJ 2003 Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18:204-212.
14. van't Hof RJ, Armour KJ, Smith LM, Armour KE, Wei XQ, Liew FY, Ralston SH 2000 Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci USA 97:7993-7998.
15. Coxon FP, Helfrich MH, van't Hof RJ, Sebti S, Ralston SH, Hamilton A, Rogers MJ 2000 Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476.
16. McGowan NW, Walker EJ, MacPherson H, Ralston SH, Helfrich MH 2001 Cytokine-activated endothelium recruits osteoclast precursors. Endocrinology 142:1678-1681.
17. van't Hof RJ 2003 Osteoclast formation in the mouse coculture assay. Methods Mol Med 80:145-152.
18. MacPherson H, Noble BS, Ralston SH 1999 Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells. Bone 24:179-185.
19. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ 1998 Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678.
20. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
21. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC 2000 Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978.
22. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
23. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC 1998 Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942-1950.